Medifast, Inc. operates the OPTAVIA coach-guided weight management and metabolic health platform but has experienced sharp revenue declines amid competition from GLP-1 medications, while maintaining a robust cash balance and limited analyst coverage pointing to a cautious "Hold" consensus.
Historical Context: The stock reached an all-time high closing price of $294.26 on May 28, 2021.
52-week range (as of late July 2026 data): $9.22 low to $15.11 high.
Interpretation: The stock has undergone a dramatic long-term decline from its 2021 peak, consistent with broader challenges in the traditional weight-loss industry.
| Period | MED Return | S&P 500 Return |
|---|---|---|
| YTD | 6.74% | 10.85% |
| 1-Year | 27.56% | 21.65% |
| 3-Year | 89.87% (cumulative?) | 68.56% |
| 5-Year | 96.08% (cumulative?) | 71.56% |
Limitation: Performance data reflects periods ending around early August 2026; past performance is not indicative of future results. Returns shown are trailing total returns where available.
Overview: TTM revenue approximately $346.1 million with net loss of $20.02 million (profit margin -5.78%).
TTM EPS: -$1.82. Strong balance sheet with ~$168.95 million in cash and equivalents (mrq) and minimal debt (Total Debt/Equity 8.15%).
| Metric | Value |
|---|---|
| Revenue (TTM) | $346.1M |
| Net Income (TTM) | -$20.02M |
| Profit Margin | -5.78% |
| ROA (ttm) | -4.33% |
| ROE (ttm) | -9.80% |
| Cash & Equivalents (mrq) | $168.95M |
| Market Cap (approx. recent) | ~$109M |
Guidance (as of Q1 2026 release): FY 2026 revenue $270M–$300M; FY 2026 loss per share $1.55–$2.75.
Interpretation: Revenue contraction reflects pressure on coach network and client acquisition; company emphasizes shift toward metabolic health and GLP-1 support plans while targeting future profitability improvements starting potentially in Q4 2026.
Uncertainty: Quarterly results and guidance are subject to change; full Q2 2026 details released August 3, 2026, with earnings call.
Links for more information:
Consensus: Hold / Neutral (limited coverage with 1-2 analysts typically).
Average price target: ~$12.00 (range $12.00–$16.50 from available analysts).
| Date | Analyst/Firm | Rating | Target |
|---|---|---|---|
| Feb 19, 2026 | Stephens & Co. | Equal-Weight / Hold | $12.00 (lowered from $15) |
| Feb 19, 2025 | D.A. Davidson | Hold | $16.50 |
Zacks Research upgraded to Strong Buy in July 2026.
Interpretation: Limited Wall Street coverage suggests lower visibility; targets imply potential upside from recent trading levels but reflect cautious outlook amid industry headwinds.
Uncertainty: Analyst estimates and ratings can shift rapidly with new earnings or market developments; only a small number of firms cover the stock.
Links for more information:
Primary Base: Health and wellness consumers in the United States seeking weight loss, weight management, and healthy living solutions via e-commerce platform and independent coach network.
Interpretation: Business model relies heavily on direct-to-consumer sales and a network of independent coaches rather than traditional retail or broad advertising.
Direct and Indirect Peers:
| Company | Type | Notes |
|---|---|---|
| WW International (Weight Watchers) | Direct program competitor | Structured weight loss with behavior change support |
| Noom | Digital program competitor | App-based behavioral coaching |
| Herbalife | Direct-selling nutrition peer | Distributor-led nutrition products |
| USANA Health Sciences | Nutritional supplements peer | Similar wellness product focus |
| Hims & Hers / Ro | Telehealth / GLP-1 substitutes | Medication access and support |
| Novo Nordisk / Eli Lilly | GLP-1 medication makers | Primary disruptors via Wegovy, Zepbound, etc. |
Interpretation: Traditional meal-replacement and coaching programs face substitution risk from GLP-1 drugs and digital alternatives; Medifast has adapted by offering nutritional support plans.
Links for more information:
Overall data limitations: Information current as of early August 2026; financials and news subject to updates. Verify with primary sources like SEC EDGAR or company IR for investment decisions. Stock performance excludes any dividends (none recent). No real-time or current pricing included.